Aurobindo recalls one lot of its epilepsy drug

Some of the capsules in the lot were found to be empty

Aurobindo Pharma's American subsidiary has initiated a voluntary recall of a batch of Gabapentin capsules, which are used in the treatment of epilepsy, as some of the capsules were found to be empty.

The empty capsules could have adverse health consequences that can range from having no effect to a short term reduction in efficiency, the US Food and Drug Administration (US FDA) said.

The company received the American drug regulator's approval to manufacture and market the product in October 2011.

 “The affected Gabapentin lot, GESB14011-A, expires on December 2015 and is packaged in 100-count bottles,” a statement available on the FDA website said. 

Aurobindo Pharma USA is notifying its distributors and customers through letters for recalling the batch, it said.

The company spokesperson said the move doesnot have any financial repurcussions.

Aurobindo shares fell as low as Rs 1,093.20 from a previous close of Rs 1,118.35 before recovering to Rs 1,098.50 in morning trade on BSE.